Abstract: An anaerobic-AO-SACR combined advanced nitrogen removal system for high ammonia-nitrogen wastewater, in which high ammonia-nitrogen wastewater first enters an anaerobic reactor to remove most of organic matters from the wastewater, effluent water enters an AO reactor for nitrogen removal by pre-denitrification in an anoxic zone and for removal of the remaining organic matters and nitrification of ammonia nitrogen in an aerobic zone, and then the effluent water enters an intermediate pool. Meanwhile, under the control of a water quality testing device and a PLC controller, a part of raw water is introduced into the intermediate pool to adjust the carbon nitrogen ratio of the wastewater.

Abstract: The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and/or treating myocardial infarction, a use in manufacture of a medicament for preventing and/or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and/or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and/or treatment of salt-sensitive hypertensive myocardial fibrosis.

Abstract: The present invention relates to a use of cellular repressor of E1A-stimulated genes (CREG) protein, and in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The present invention also relates to a use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The invention also relates to a corresponding kit, such as a kit used for the predication and/or evaluation of therapeutic effect and prognosis of a fatty liver disease and type 2 diabetes.

Abstract: Described is the use of an E1A activating gene repressor (CREG) protein, in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases. Also described is the use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases.

Abstract: The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and/or treating myocardial infarction, a use in manufacture of a medicament for preventing and/or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and/or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and/or treatment of salt-sensitive hypertensive myocardial fibrosis.